Pharmaceutical

Lilly wins tentative approval for diabetes drug

August 20, 2014
 IBJ Staff
Final approval could be delayed until mid-2016 due to a claim of patent infringement by drugmaker Sanofi.
More

Cardinal Health unit seeks tax breaks for local drug facility

August 18, 2014
 IBJ Staff
A subsidiary of Dublin, Ohio-based Cardinal Health Inc. is seeking tax breaks from the city of Indianapolis to help it open a $14.4 million local drug-production facility that would employ 85 workers by 2017.
More

Eli Lilly making renewed push in biotech field, where it once pioneered

August 16, 2014
J.K. Wall
Lilly expects to soon announce late-stage clinical trial results for two biotech drugs designed to slow the inflammation caused by autoimmune diseases. By the end of the year, it will announce results for a third.
More

Indy startup has rare disease in its sights

August 9, 2014
J.K. Wall
Founders of Chondrial Therapeutics believe that if further testing validates their treatment for Friedreich’s ataxia, it could be a blockbuster with annual sales topping $1 billion.
More

FDA approves Lilly, Boehringer diabetes drug

August 1, 2014
Associated Press
The Food and Drug Administration said Friday it will permit Jardiance tablets to be used by adult patients with type 2 diabetes who also are trying to control their condition with diet and exercise.
More

Roche drug trial backs Lilly on Alzheimer’s findings

July 28, 2014
J.K. Wall
Results of a Roche clinical trial mirror those produced by an experimental Lilly drug two years ago. Lilly executives say that validates their approach in the multi-billion-dollar race to market the first drug to reverse Alzheimer's.
More

UPDATE: Four doctors arrested in clinic raids

July 25, 2014
Associated Press
Dr. Larry Ley, 68, of Noblesville, was being held on $1 million bond on drug-dealing charges in Hamilton County Jail. A dozen additional suspects, including three other doctors, were either under arrest or being sought by police.
More

Regenstrief taps Deloitte to pick up more health care industry clients

July 14, 2014
J.K. Wall
With federal health research funding in decline, Indianapolis-based Regenstrief Institute Inc. wants to make up the difference by serving pharmaceutical companies, medical device makers, health insurers and hospital systems.
More

Express Scripts cuts payments for customized drugs

July 3, 2014
Associated Press
The nation's largest pharmacy benefit manager, Express Scripts, is dramatically scaling back its coverage of compounded medications, saying most of the custom-mixed medicines are ineffective or overpriced.
More

Lilly wins EU backing for version of insulin drug

June 27, 2014
Bloomberg News
Lantus, which garnered $7.8 billion in sales for Paris-based Sanofi in 2013, loses patent protection in Europe in May next year.
More

Merck's exit pushes Endocyte shares lower

June 18, 2014
 IBJ Staff
Shares of Endocyte Inc. skidded 15 percent Wednesday after industry giant Merck & Co. Inc. decided it would give up on developing Endocyte cancer drug vintafolide.
More

Lilly, IU expect $25M plan to create new model for drug R&D

June 16, 2014
J.K. Wall
A new research consortium spearheaded by the Indiana University School of Medicine and Eli Lilly and Co. could bring in $25 million to $50 million over five years to create a new approach for developing drugs that provide more precise treatment for small groups of patients.
More

Doctors want to improve state drug-tracking system

June 9, 2014
Associated Press
A study has found that most doctors in Indiana aren't frequently using an electronic system designed to detect prescription drug abuse.
More

Glaxo to pay $105 million in multistate settlement

June 4, 2014
Bloomberg News
Indiana will receive part of the settlement money. The accord will prohibit Glaxo from providing incentive payments to salespeople that encourage uses of the drugs not indicated on their labels.
More

Lilly, Sanofi seek to sell erection drug Cialis without prescription

May 28, 2014
 Bloomberg News and IBJ Staff
Sanofi will apply for approval of Cialis as an over-the-counter treatment in the United States, Europe, Canada and Australia. The drug garnered $2.16 billion in sales last year.
More

Pfizer pulls plug on push to buy AstraZeneca

May 26, 2014
Associated Press
Pfizer said Monday that it does not intend to make a takeover offer for British drugmaker AstraZeneca, pulling the plug for now on what would have been the largest deal in the industry's history.
More

Takeda denies hiding Actos cancer risks in Nevada trial

May 21, 2014
Associated Press
Takeda Pharmaceutical Co. didn’t hide the alleged bladder-cancer risks of its diabetes medicine Actos, a lawyer for the company told a jury. Actos was marketed for Takeda in the United States by Eli Lilly and Co. from July 1999 to March 2006.
More

Drugmaker hid diabetes drug’s cancer risks, lawyer says

May 19, 2014
Bloomberg News
Takeda Pharmaceutical Co. executives covered up the cancer risks of its diabetes medicine Actos to protect billions of dollars in sales, a lawyer for two women argued.
More

Lilly's latest sales strategy: the soft sell

May 17, 2014
J.K. Wall
Eli Lilly and Co. thinks it has a secret weapon to return to growth. No, it’s not a new blockbuster drug—although Lilly will most likely have several new products hit the market this year and next. Rather, it’s an unorthodox, softer approach put into play by its U.S. sales force.
More

Lilly loses patent dispute over Alimta in London court

May 15, 2014
Bloomberg News
Eli Lilly and Co. lost a United Kingdom lawsuit over its Alimta cancer treatment when a judge ruled Thursday that a generic version planned by Actavis Plc doesn't breach European patents.
More

Lilly to appeal $450M ruling over poisoned workers in Brazil

May 12, 2014
 IBJ Staff
Brazilian federal prosecutors had accused a Lilly subsidiary of incinerating toxic waste at the plant that it operated until 2003.
More

Lilly says its once-daily insulin tops competitor's drug

May 12, 2014
Bloomberg News
Eli Lilly & Co. said its experimental insulin helped diabetic patients more than Sanofi’s biggest product in studies that also raised some safety risks.
More

Bayer’s $14.2 billion Merck buy shows pharma strategy split

May 7, 2014
Bloomberg News
Bayer AG's $14.2 billion acquisition of Merck & Co. is the latest in a series of big pharma deals and it exposes a deepening split in the way drugmakers approach their portfolios.
More

Endocyte shares plunge 60 percent after drug trial is stopped

May 2, 2014
 Bloomberg News and IBJ Staff
Endocyte Inc.'s stock fell more than 60 percent in early trading Friday after the drug it’s developing with Merck & Co.’s backing failed to help patients in a trial for ovarian cancer.
More

Drug prices surge as generics, niche treatments eat profit

May 1, 2014
Bloomberg News
Since 2007, the cost of brand-name medicines has jumped, with prices doubling for dozens of established drugs that target everything from multiple sclerosis to cancer, blood pressure and even erections, according to an analysis conducted for Bloomberg News.
More
Page  1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Socialized medicine works great for white people in Scandanavia. It works well in Costa Rica for a population that is partly white and partly mestizo. I don't really see Obamacare as something aimed against whites. I think that is a Republican canard designed to elicit support from white people for republican candidates who don't care about them any more than democrats care about the non-whites they pander to with their phony maneuvers. But what is different between Costa Rica nd the Scandanavian nations on one hand and the US on the other? SIZE. Maybe the US is just too damn big. Maybe it just needs to be divided into smaller self governing pieces like when the old Holy Roman Empire was dismantled. Maybe we are always trying the same set of solutions for different kinds of people as if we were all the same. Oh-- I know-- that is liberal dogma, that we are all the same. Which is the most idiotic American notion going right back to the propaganda of 1776. All men are different and their differences are myriad and that which is different is not equal. The state which pretends men are all the same is going to force men to be the same. That is what America does here, that is what we do in our stupid overseas wars, that is how we destroy true diversity and true difference, and we are all as different groups of folks, feeling the pains of how capitalism is grinding us down into equally insignificant proletarian microconsumers with no other identity whether we like it or not. And the Marxists had this much right about the War of Independence: it was fundamentally a war of capitalist against feudal systems. America has been about big money since day one and whatever gets in the way is crushed. Health care is just another market and Obamacare, to the extent that it Rationalizes and makes more uniform a market which should actually be really different in nature and delivery from place to place-- well that will serve the interests of the biggest capitalist stakeholders in health care which is not Walmart for Gosh Sakes it is the INSURANCE INDUSTRY. CUI BONO Obamacare? The insurance industry. So republicans drop the delusion pro capitalist scales from your eyes this has almost nothing to do with race or "socialism" it has to do mostly with what the INSURANCE INDUSTRY wants to have happen in order to make their lives and profits easier.

  2. Read the article - the reason they can't justify staying is they have too many medicare/medicaid patients and the re-imbursements for transporting these patient is so low.

  3. I would not vote for Bayh if he did run. I also wouldn't vote for Pence. My guess is that Bayh does not have the stomach to oppose persons on the far left or far right. Also, outside of capitalizing on his time as U. S. Senator (and his wife's time as a board member to several companies) I don't know if he is willing to fight for anything. If people who claim to be in the middle walk away from fights with the right and left wing, what are we left with? Extremes. It's probably best for Bayh if he does not have the stomach for the fight but the result is no middle ground.

  4. JK - I meant that the results don't ring true. I also questioned the 10-year-old study because so much in the "health care system" has changed since the study was made. Moreover, it was hard to get to any overall conclusion or observation with the article. But....don't be defensive given my comments; I still think you do the best job of any journalist in the area shedding light and insight on important health care issues.

  5. Probably a good idea he doesn't run. I for one do not want someone who lives in VIRGINIA to be the governor. He gave it some thought, but he likes Virginia too much. What a name I cannot say on this site! The way these people think and operate amuses me.

ADVERTISEMENT